Haim Bio Co., Ltd.
🇰🇷South Korea
MTD, Safety and Efficacy of NYH817G and NYH100P in Monotherapy and Combination in Patients With Advanced Solid Tumors
Phase 1
- Conditions
- Advanced Solid Tumors
- Interventions
- First Posted Date
- 2020-02-10
- Last Posted Date
- 2020-10-20
- Lead Sponsor
- Haim Bio Co., Ltd.
- Target Recruit Count
- 42
- Registration Number
- NCT04262739
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath